Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Characteristics of studies included based on treatment regimens: standard chemotherapy regimen (anthracycline, cyclophosphamide, taxanes) and carboplatin

From: Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

 

Affiliation

Type of study

Stage of disease

Nº of BRCA1/2 mutated TNBC patients

pCR

Neoadjuvant treatment

Fontaine 2019 [26]

Belgium

RCT phase II

II-III

9

7

Cb-P + E-C

Sella 2018 [35]

Israel

Clinical trial

I-III

14

9

Cb-P-Dox-C

Walsh 2019 [36]

Irland

Retrospective

I-III

6

4

Cb-P + Dox-C

Loib 2018

BrighTNess [37]

USA

RCT phase III

II-III

24

12

Cb-P- Dox-C

  1. pCR Pathological complete response, Cb Carboplatin, Dox Doxorubicin, P Paclitaxel, E Epirubicin, C Cyclophosphamide